RxDoctor Payments Data

Elizabeth Rice

Acute Care · Dallas, TXNPI 1568913051

Payments from drug & device makers

$6,286in general payments, 2019–2025

Across 212 payments — averaging $29.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$815
  • Merck$758
  • UCB, Inc.$669
  • Novartis$479
  • Abbott$265
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$84013%
  • Food & beverage$5,28884%
  • Education$1032%
  • Other$561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,286 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$60,050
Medicare patients
304
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$135,262
XareltoRivaroxaban54$51,081
JardianceEmpagliflozin34$37,067
EntrestoSacubitril/Valsartan20$24,421
FarxigaDapagliflozin Propanediol19$16,834
Repatha SureclickEvolocumab14$16,477
Losartan Potassium159$1,975
Metoprolol Succinate160$1,580
Potassium Chloride52$1,280
Atorvastatin Calcium122$1,083
Ezetimibe55$1,027
Amiodarone Hcl12$1,007
Torsemide43$965
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$959
Rosuvastatin Calcium60$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$193$135,262116 claims
Johnson & JohnsonXarelto$98$51,08154 claims
Boehringer IngelheimJardiance$254$37,06734 claims
NovartisEntresto$479$24,42120 claims
AstraZenecaFarxiga$79$16,83419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.

Other acute care in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →